Needham & Company analyst Chad Messer raised the price target on Cytokinetics (NASDAQ: CYTK) to $24.00 (from $16.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE